LEIDEN, The Netherlands, July 6, 2012 /PRNewswire/ --
HAL Allergy B.V. announced that it succeeded in extending its GMP contract manufacturing activities for clinical batch supply of both recombinant and viral products. The Dutch inspectorate granted the permit extension after inspection of the operational activities in the BSL2 clean rooms and development laboratory in June 2012.
In 2009 HAL Allergy opened its state-of-the-art production facility at the Bio Science Park in Leiden. In order to offer the competences of its pharmaceutical specialists to customers in need of reliable GMP services, the business was expanded into contract manufacturing. During the start up of this new business, the cooperation with the contract research organization Batavia Bioservices, for process know how and Yxion for engineering were crucial.
“The fact that the Dutch authorities extended our GMP permit, is a big step forward in our goal of becoming a key biotech service company. Our team of specialists offer our clients reliable and effective services. Modern production- and laboratory facilities and over 50 years experience in vaccine production will be key asset in partnerships with our customers” says Harry Flore, CEO of HAL Allergy.
About HAL Allergy
The HAL Allergy Group (http://www.hal-allergy.com) was established in 1959 and is an important European manufacturer of allergy vaccines and diagnostics. Today HAL Allergy is a modern company with high quality pharmaceutical, manufacturing and research facilities and many years of GMP tradition. The Group’s products are distributed via subsidiaries in Germany, Spain, Italy, Poland, Austria and the Benelux as well as a network of distribution partners around Europe. Currently HAL Allergy employs over 280 people throughout Europe with more than 160 situated in the Netherlands HQ.
SOURCE HAL Allergy Group
